Optimal Sequence of Daratumumab and Elotuzumab in Relapsed and Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia and Lymphoma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Optimal Sequence of Daratumumab and Elotuzumab in Relapsed and Refractory Multiple Myeloma
Leukemia and Lymphoma 2019 Nov 18;[EPub Ahead of Print], E Hoylman, A Brown, AJ Perissinotti, BL Marini, M Pianko, JC Ye, E Campagnaro, VR NacharFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.